These findings suggest a potential AP-1/PD-1 axis which could be exploited as a future therapeutic option for CHL, especially since PD-1 and its ligands have already highlighted the clinical efficacy of targeted immunotherapy [105]. Here, JUN is linked to classic Hodgkin lymphoma.